Compare National Beverage Corp. (FIZZ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Novo Nordisk A/S — how do they compare? National Beverage Corp. trades at $31.72 (market cap $2.89B), while Novo Nordisk A/S trades at $51.52 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 76.9× National Beverage Corp.'s market cap, and Novo Nordisk A/S pays a 3.56% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.
| FIZZ | NVO | |
|---|---|---|
Market Cap | $2.89B | $222.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $47.69 | $71.70 |
52-Week Low | $30.85 | $35.29 |
Enterprise Value | $2.60B | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $31.47, up 1.78% today, but faces bearish technical signals with three consecutive earnings misses. The company maintains solid profitability with 15.56% net margins and 34.03% ROE, though revenue growth has stalled at $1.2B annually. Recent news highlights a $3.25 special dividend announcement but also concerns about LaCroix brand decline and muted growth prospects.
The outlook remains cautious with analyst sentiment skewed bearish (50% sell ratings) and technical indicators pointing downward. While the dividend provides shareholder return, fundamental challenges including competitive pressures and stagnant revenue create headwinds for meaningful price appreciation in the near term.
Novo Nordisk (NVO) trades at $49.07, down 0.43% on the day, amid a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 37.2% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EU approval for its Wegovy weight-loss pill, reinforcing its competitive position in the GLP-1 market.
The outlook remains positive given earnings momentum and expanding product approvals, though risks include rising competition from generics and potential prescription slowdowns. Analyst consensus is bullish with 57.9% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
